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TSP1Obesity is associatedwith podocyte injury and the development of proteinuria. Elevated plasma free fatty acid is
one of the characteristics of obesity and has been linked to podocyte dysfunction. However, the mechanisms re-
main unclear. In the current study, we examined the effect of saturated free fatty acid (FFA) on human podocyte
apoptosis and function in vitro. The mechanism and its in vivo relevance were also determined. We found that
FFA treatment inducedhumanpodocyte apoptosis and dysfunction,whichwas associatedwith increased expres-
sion of a matricellular protein-thrombospondin1 (TSP1). FFA stimulated TSP1 expression in podocytes at the
transcriptional levels through activation of MAPK pathway. Addition of puriﬁed TSP1 to cell culture media in-
duced podocyte apoptosis and dysfunction. Tis effect is though a TGF-β independentmechanism.Moreover, pep-
tide treatment to block TSP1 binding to its receptor-CD36 attenuated FFA induced podocyte apoptosis, suggesting
that TSP1/CD36 interaction mediates FFA-induced podocyte apoptosis. Importantly, using a diet-induced obese
mouse model, in vivo data demonstrated that obesity-associated podocyte apoptosis and dysfunction were at-
tenuated in TSP1 deﬁcientmice aswell as in CD36 deﬁcientmice. Taken together, these studies provide novel ev-
idence that the interaction of TSP1 with its receptor CD36 contributes to obesity — associated podocytopathy.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
In the United States, about one third of adults are overweight
(25 kg/m2 ≤ body mass index (BMI) ≤ 29.9 kg/m2) and one third are
obese (BMI≥ 30 kg/m2) [1].With the recent elevation in the prevalence
of obesity worldwide, renal complication emerges to be an important
issue for individuals who suffer from this disease. Obesity increases
the susceptibility of chronic kidney disease (CKD) because obesity
largely mediates diabetes and hypertension, which are the ﬁrst two
risk factors for CKD. Besides this, obesity also has its independent effects
on renal damage, known as hyperleptinemia and hyperlipidemia [2].
Albuminuria is one the most common symptoms in people with
obesity-associated glomerular injury, which is characterized as glomer-
uli enlargement, focal segmental glomerulosclerosis, basement mem-
brane thickening, and podocyte damage [3]. Recent studies focusing
on podocyte physiology have indicated that podocyte structural and
functional integrity is required for preventing glomerular albuminlogy and Nutritional Sciences,
S. Limestone Street, Lexington,
3646.leakage and subsequent albuminuria [4,5]. Previous study suggested
that high glucose-induced oxidative stress initiated podocyte apoptosis
and depletion both in vivo and in vitro [6], which represents an early
mechanism driving diabetic nephropathy. However, the exact mecha-
nism whereby podocytes were destroyed under obese condition is
still poorly understood.
Thrombospondin-1 (TSP1) is a multifunctional extracellular matrix
protein and can be produced by kidney cells, including podocytes,
mesangial cells and tubular cells. Accumulating evidence suggest that
through activating latent transform growth factor-beta (TGF-β), TSP1
plays an important role in the development of several kidney diseases,
including diabetic nephropathy, obstructive kidney disease and renal
ischemia-reperfusion injury [7–10]. Our previous study demonstrated
that elevated TSP1 involved in insulin resistance and adipose tissue in-
ﬂammation by regulating macrophage accumulation in a diet-induced
obese mouse model [11]. Moreover, we have revealed that obesity
associated renal hypertrophy, albuminuria and ﬁbrosis was abolished
in TSP1 deﬁcient mice [12], suggesting the important role of up-
regulated TSP1 in obesity-associated kidney damage. Importantly,
both in vivo and in vitro evidence indicated that TSP1 induces endothe-
lial cell apoptosis through mitochondrial-dependent and -independent
pathway by binding to CD36 [13,14], which expresses on the surface
of many types of cells, including podocyte [15,16]. Based on these
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through a CD36-dependentmanner under obese conditions. To test this
hypothesis, in current study, saturated free fatty acid (FFA, palmitate) or
human recombinant TSP1was used to induce humanpodocyte injury. A
peptide to block TSP1 binding to CD36 was used in the mechanism
studies. Moreover, the in vivo relevance was determined by using a
diet-induced obesity mouse model in either TSP1 deﬁcient mice or
CD36 deﬁcient mice.2. Materials and methods
2.1. Human podocyte culture and treatments
Immortalized human podocytes (generously provided by Dr. Moin
Saleem from Bristol Royal Hospital for Children, Bristol, UK) were
used. These cells were cultured and differentiated as described previ-
ously [17]. These podocytes were propagated at 33 °C in medium with
RPMI medium1640 (Gibico), 10% fetal bovine serum (FBS, Gibico),
100 U/ml penicillin-streptomyci (Gibico) and 1% insulin transferrin
selenium A (Gibico). To induce differentiation, the podocytes were
transferred to a 37 °C condition for 10–14 days before starting
experiment.
After starving in RPMI-1640 medium containing 0.5% bovine serum
albumin (BSA, Sigma) for 24 h, podocyteswere undertook the following
treatment: (a) podocytes were treated with 25 μM or 125 μM of palmi-
tate (Sigma) for 24 h and equivalent amounts of fatty acid-free BSA
were added to the control group. (b) Podocytes were treated with
1 μg/ml of TSP1 (R&D System) for 24 h in the presence or absence of
anti-TGF-β1,2,3 antibody (15 μg/ml from R&D system), and equivalent
amounts of PBS were added to the control group. (c) Podocytes were
pre-incubated for 2 h with the following MAPKs inhibitors: PD98059
(ERK p42/44 inhibitor, at 10−5 mol/l, Sigma), SB202190 (p38 inhibitor,
at 10−5 mol/l, Sigma) and SP600125 (JNK inhibitor, at 10−5 mol/l,
Sigma) and then treated with 125 μM of palmitate for 24 h.
(d) Podocytes were preincubated with 2 μg/ml CD36 speciﬁc peptide
(YRVRFLAKENVTQDAEDN, p(93–110) [18,19] to block TSP1 binding to
CD36) or scrambled control peptide (RFAYLRKNVTENDEQAVCD)
(from American Peptide Company Inc.) for 2 h, followed by treatment
with 125 μM of palmitate for another 24 h. After treatment, cells were
harvested for podocyte apoptotic and functional markers detection, as
well as TSP1 expression in both mRNA levels and protein levels.2.2. Isolation of murine podocytes and treatments
Isolation of podocytes from CD36 knockoutmice (on C57BL6/J back-
ground, kindly provided by Dr. Deneys van der Westhuyzen at Univer-
sity Kentucky), TSP1 knockout mice (Jackson laboratory), or control
wild type mice was performed as described previously [20,21]. Brieﬂy,
glomeruli were isolated from mice [21] and plated on collagen type I-
coated dishes at 37 °C in RPMI-1640 medium with 10% FBS, 100 U/ml
penicillin, 100 μg/ml streptomycin, 100mMHEPES, 1mMsodiumbicar-
bonate, and 1 mM sodium pyruvate to allow glomerular podocytes to
grow out. Subculture of primary podocyteswas performedby detaching
the glomerular cells with 0.25% trypsin-EDTA, followed by sieving
thought 40 μm cell strainer, and cultured on type 1 collagen coated
dishes. Podocytes of passages 1 or 2 were used for the experiments.
CD36−/− podocytes or wild type podocytes were treated with
125 μM of palmitate (Sigma) or control BSA for 24 h. After treatment,
cells were harvested. TSP1 expression in both mRNA levels and protein
levels were determined by PCR and western blotting, respectively.
TSP1−/− podocytes or wild type podocytes were treated with
125 μM of palmitate (Sigma) or control BSA for 24 h. After treatment,
caspase 3 activity was analyzed by using caspase-3 colorimetric assay
kit (R&D). BSA ﬁlter assay was also analyzed in these cells.2.3. Experimental animals and protocols
All experiments involvingmice conformed to the National Institutes
of Health Guide for the Care and Use of Laboratory Animals and were
approved by the University of Kentucky Institutional Animal Care and
Use Committee. Male TSP1−/− mice (on C57BL6/J background, kept
in our lab) and CD 36−/−mice (on C57BL6/J background, kindly pro-
vided by Dr. Deneys van der Westhuyzen at University Kentucky) at
eight weeks of age and age-matched wild type littermate controls
were used [11,12,22]. Mice were housed in a temperature controlled
room with a 12 h light/dark cycle. Mice were fed a low fat (LF) (10%
kcal as fat; D12450B; research Diets, Inc., NJ) or a high fat (HF) diet
(60% kcal as fat; D12492, research Diet, Inc., NJ) for 16 weeks. Each
group contained 6–10 mice. The data relating to the metabolic pheno-
type of these mice was previously published [11,12,22] and the kidney
samples of these mice were further analyzed in the current study.
2.4. Podocyte BSA ﬁlter assay
The transepithelial permeability of control and FFA treated
podocytes was assessed by measuring the passage of BSA across the
human podocyte monolayer as described previously [23]. Human
podocytes at density of 5 × 105 were seeded into collagen-coated
transwell-Col PTFEﬁlter (3 μmpore, Corning) and cultured under differ-
entiating conditions for 10–14 days. Cells were then treated with
125 μM of palmitate or control BSA for 24 h. After treatment, cells
were washed twicewith PBS. The upper compartmentwas then reﬁlled
with 0.5 ml RPMI 1640 and the lower compartment with 1 ml BSAme-
dium (RPMI 1640 supplementedwith 40mg/ml BSA) and incubated for
2 h or as indicated at 37 °C. Total protein concentration in the upper
compartment was determined using a Bio-Rad protein assay (Bio-Red
Laboratories) [24].
2.5. mRNA stability assay
After starving for 24 h, human podocytes were treated with 125 μM
of palmitate or control BSA for another 24 h. Thenmedia were removed
and actinomycin D (5 μg/ml, Sigma) was added (designated as t = 0).
After different periods of incubation, cells were harvested. Real-time
PCR analysis for TSP1 mRNA was performed. Measurement of the ratio
of TSP1/18S at t = 0 (from actinomycin D treatment) was assigned a
relative value of 100% as we did before [25].
2.6. TSP1 promoter-reporter constructs and luciferase assay
TSP1 promoter-luciferase reporter constructs [TSP1 (−2033)] were
generated using pGL3-basic vector (Promega) as described previously
[26]. Human podocytes were cultured in 12-well plate and transiently
transfected using Effectene transfection reagent (Qiagen) with 0.3 μg
of TSP1 promoter luciferase reporter plasmid. pRL-SV40 (0.006 μg,
Promega) was used as an internal control for transfection. Transfected
cells were treated with 125 μM of palmitate or control BSA for 24 h,
and luciferase activities were analyzed using the dual-luciferase assay
kit (Promega) according the manufacture's protocol as described previ-
ously [25].
2.7. Renal immunohistochemical and immunoﬂuorescence staining
For immunohistochemical staining: kidney tissue sections were
deparafﬁnized in xylene, and were rehydrated in graded mixtures of
ethanol/water. Endogenous peroxidase activity was blocked with 3%
H2O2 for 10 min at room temperature. The slides were placed in PBS
buffer containing 5% Bovine Serum Albumin (BSA) for 30 min. Anti-
cleaved caspase-3 (Cell signaling) antibody was applied for 1 h at
room temperature. A negative controlwas included by substituting con-
trol IgG for the primary antibody. After washing with PBS, biotinylated
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ing, an avidin-biotin-peroxidase complex was applied to the slides for
30 min. The slides were washed once again with PBS before color
development with DAB using Vectastain ABC system (Vector Lab). For
immunoﬂuorescence staining: frozen kidney samples were sectioned
and ﬁxed in cold acetone for 10–15min. After blocking in 5% BSA, slides
were incubated with anti-WT1 antibody (Santa Cruz) for 1 h and then
with Alex Fluor 568 conjugated secondary antibody (Life Technologies)
for 45 min. After washing, slides were incubated with DAPI for 5 min
and coverslipped. The images were taken under ﬂuorescentmicroscope
and WT1 positive cells in glomerulus were counted.
2.8. Apoptosis detection
2.8.1. TUNEL staining
Apoptotic nuclei were detected using a transferase-mediated dUTP
nick-end labeling (TUNEL) staining of cultured podocyte or kidney sec-
tions. TUNEL staining was performed according to the manufacturer's
instructions (Roche). For podocyte staining, slides with cells were
rinsed with PBS. 50 μl of TUNEL reaction mixture or labeled solution
was added on the section and incubated for 60 min at 37 °C in
the dark. After washing with PBS, sections were mounted with DAPI
mountingmediumand then analyzed under a ﬂuorescencemicroscope.
For kidney tissue, 4 μm parafﬁn-embedded kidney sections were
deparafﬁnized with xylene and rehydrated through a graded series of
ethanol. After blocking in 0.1 M Tris–HCl containing 3% BSA and 20%
FBS at room temperature for 30 min, 50 μl of TUNEL reaction mixture
or labeled solution was added on the section and incubates for 60 min
at 37 °C in a humidiﬁed atmosphere in the dark. After counter staining
for nuclei, slides were dehydrated, cleared and mounted. Cells with
brown granules in nuclei were TUNEL positive cells and TUNEL positive
podocytes were counted in 30 glomeruli of kidney section. The average
numbers of TUNEL-positive podocytes per glomerulus was calculated.
2.8.2. Annexin V and propidium iodide (PI) staining
After treatment, cells were harvested and washed in PBS and
suspended in Annexin V binding buffer (10 mM HEPES, 140 mM NaCl,
and 2.5 mM CaCl2, pH 7.4). Annexin V Alexa Flour 488 (Life technology)
was added and cells were incubated in the dark for 15min at room tem-
perature. Then, 1: 10 diluted propidium iodide (Sigma) were added into
cells and incubated in the dark for 15 min at room temperature. After
washing, cells were collected and analyzed by ﬂow cytometry (using ser-
vice from the Flow Cytometry Core Facility at University of Kentucky).
Annexin V positive and PI negative cells were considered apoptotic.
2.9. Caspase-3 activity detection
Caspase-3 activity was analyzed by using caspase-3 colorimetric
assay kit (R&D). Add 50 μl of cell lysate or kidney cortex homogenate
(100–200 μg of total protein) into each well of a 96well ﬂat bottommi-
croplate and 50 μl 2 × reaction buffer 3. Incubate the plate at 37 °C for
1–2 h after adding 50 μl of caspase-3 colorimetric substrate into eachTable 1
Primer sequences used in the study.
Genes Forward (5′–3′)
hWT1 TACAGATGCATAGCCGGAAG
hCD36 CCCTGTTACTACCACAGTTG
hNephrin CTCGGACCAAACCAACAT
hSynaptopodin AGGTGAGATGCAGCACACTCC
hTSP1 TTCCGCCGATTCCAGATGATT
mCD36 ACTGGTGGATGGTTTCCTAGC
mNephrin ACAAGAAGCTCCACGGTTAGC
mSynaptopodin GTCTCCAGACATCTTCCCTTTCwell. Read the plate on a microplate reader using a wavelength of
405 nm and the OD values were used for further analyzing.
2.10. Western blotting analysis
Mouse kidney cortex or podocyteswere homogenized in lysis buffer.
After concentration being measured, protein was subjected to SDS-
PAGE gel under reducing condition and transferred onto a nitrocellulose
membrane. After blocking with 5% milk, the membrane was incubated
with anti-GAPDH (Millipore), anti-TSP1 (Thermo Scientiﬁc), anti-WT1
(Santa Cruz), anti-Nephrin (Santa Cruz), anti-cleaved caspase-3 (Cell
signaling), anti-caspase-3 (Cell signaling) and anti-BAD (Cell signaling)
antibodies at 4 °C overnight. Afterwashing, themembranewas incubated
with horseradish peroxidase-conjugated secondary antibody (Jackson
Labs). The reaction was visualized using an enhanced chemilumines-
cence system (Pierce). Immunoblots were analyzed by scanning densi-
tometry and quantiﬁed by Quantity One gel Analysis software (Bio-Rad
Laboratories).
2.11. Real-time PCR
Total RNA was isolated from glomeruli or podocytes using TRIzol
reagent (Invitrogen) and treated with DNaseI (Roche). The treated
RNA was cleaned up using an RNeasy kit (Qiagen). Two micrograms of
total RNA was used for cDNA synthesis with a High Capacity cDNA
Reverse Transcription kit (Invitrogen). Real-time PCR analyses were
performed using a SYBR Green PCR Master Mix kit with a MyiQ Real-
time PCR Thermal Cycler (Bio-Rad Laboratories). All reactions were
performed in triplicate in a ﬁnal volume of 25 μl. Dissociation curves
were run to detect nonspeciﬁc ampliﬁcation, and we conﬁrmed that
single products were ampliﬁed in each reaction. The quantities of each
test gene and internal control 18S RNA were then determined from
the standard curve using MyiQ system software, and mRNA expression
levels of test genes were normalized to 18S RNA levels as described
previously. The primer sequences were illustrated in Table 1.
2.12. Statistical analysis
Data are the mean ± SE. Differences between groups were deter-
mined by one-way ANOVA followed by Turkey's post hoc tests or
Student's t-test as appropriate. The signiﬁcance level was P b 0.05.
3. Results
3.1. Saturated free fatty acid (FFA) induced human podocyte apoptosis and
increased podocyte permeability
Previous studies reported that immortalized murine podocytes are
susceptible to the saturated FFA (palmitic acid) induced lipotoxicity
and undergo apoptosis [27–29]. In the current study, similarly, we
found that saturated FFA (palmitate) treatment induced immortalized
human podocytes apoptosis. TUNEL positive cells were increased byReverse (5′–3′)
CACA TCACACCTGTGTGTCTCCTTTGGT
ATGTCGCAGTGACTTTCC
CCTCATACCTGATGCAGAAC
TAA ATGAGCAGGGAGCTGGACATGAAA
CCT ACGAGTTCTTTACCCTGATGGCGT
CTT TTTCTCGCCAACTCCCAGGTACAA
ACA AGGCTTGGCGATATGACACCTCTT
GACTTCCCACCCAGGTTTATT
BAD
GAPDH
Control 25µM 125µM
A
C
B
Control 25µM 125µM
C-Caspase 3
Caspase 3A
po
pt
o
s
is
 c
e
lls
/F
ile
d
Co
ntr
ol Mμ
25
Mμ
12
5
0
5
10
15
*
*
D
en
s
ito
m
e
tr
y
(B
AD
/G
AP
D
H)
Co
ntr
ol
25
µM
12
5µ
M
0.0
0.5
1.0
1.5
2.0
2.5
*
*
_______________
FFA
D
e
n
s
ito
m
e
tr
y
(C
le
a
v
e
d 
Ca
s
pa
se
-3
/C
a
s
pa
se
-3
)
Co
ntr
ol
25
µM
12
5µ
M
0
1
2
3
4
*
*
_______________
FFA
Fig. 1. Free fatty acid (FFA) induced human podocyte apoptosis. Podocyteswere treatedwith 25 μMor125 μMof palmitate for 24 h and then tunnel staining for podocyteswas undertaken.
Semiquantitative analysis was performed by calculating the apoptosis cells/ﬁled (A). In addition, cleaved-caspase 3 (B) and bcl-2-associated death promoter protein (BAD) (C) protein
levels were analyzed by Western blot assay. Data are presented as mean ± SE (n = 3 individual experiments). *, P b 0.05 vs. control group.
Control 25µM 125µM
WT1
GAPDH
C D
A B
Control 25µM 125µM
GAPDH
Nephrin
E
D
e
n
s
ito
m
e
tr
y
(W
T1
/G
AP
D
H)
Co
ntr
ol
25
µM
12
5µ
M
0.0
0.5
1.0
1.5
*
_______________
FFA
D
e
n
s
ito
m
e
tr
y
(N
e
ph
rin
/G
AP
D
H)
Co
ntr
ol
25
µM
12
5µ
M
0.0
0.5
1.0
1.5
*
*
_______________
FFA
N
ep
hr
in
 m
RN
A/
18
S 
RN
A
Co
ntr
ol
25
µM
12
5µ
M
0.0
0.5
1.0
1.5
* *
_______________
FFA
W
T1
 m
R
N
A
/1
8S
 R
NA
Co
ntr
ol
25
µM
12
5µ
M
0.0
0.5
1.0
1.5
* *
_______________
FFA
B
SA
 (m
g/m
l)
Co
ntr
ol
25
µM
12
5µ
M
0
5
10
15
20
25
*
_______________
FFA
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cluding cleaved caspase-3 and bcl-2-associated death promoter protein
(BAD) were signiﬁcantly increased in FFA treated human podocytes
(Figs. 1B–C). Conversely, podocyte functional markers including WT1
and Nephrin, were decreased by FFA treatment (Figs. 2A–D). Moreover,A B
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sion in human podocytes at transcriptional level and MAPK pathway was
involved
TSP1 is an important player in obesity and diabetes associated renal
complications [8,12,26,30–32]. Moreover, saturated FFA stimulated
TSP1 expression in macrophages [33]. Therefore, we determined
whether FFA could stimulate TSP1 expression in podocytes. As shown
in Figs. 3A–B, FFA treatment stimulated TSP1 expression (mRNA and
protein levels) in human podocytes. TSP1 protein levels in the condi-
tionedmedia were also increased by FFA treatment (Fig. 3C). Moreover,
to determinewhether FFA induced TSP1 gene expression is at transcrip-
tional level, TSP1mRNA stabilitywas tested. After 24 h of FFA treatment,
actinomycin D was added to cell culture media to inhibit de novo RNA
synthesis. After designated time points, cells were harvested for analyz-
ing TSP1 mRNA levels. As shown in Fig. 3D, TSP1 mRNA stability was
unaffected by FFA treatment, suggesting that FFA-mediated increase in
TSP1mRNA levels is not due to the alteration inmRNA stability and fur-
ther supporting the transcriptional mechanism. Thus, the effect of FFA
treatment on the transcriptional activity of the TSP1 promoter wasA B
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Fig. 6. TSP1 treatment induced podocyte apoptosis and functional change through a TGF-β in
Annexin V/PI staining for podocytes (A) and podocyte BSA ﬁlter assay (B) were performed. H
for 30 min and then treated with TSP1 for 24 h. After treatment, apoptotic cells (C) and BSA ﬁ
ments). *, P b 0.05 and **, P b 0.01 vs. control group.determined using the construct and method as previously described
[26]. A full-length human TSP1 promoter-luciferase reporter construct
was transiently transfected into podocytes. We found that 24-h FFA
treatment signiﬁcantly stimulated the transcriptional activity of the
TSP1 promoter (Fig. 3E). Taken together, these data suggest that FFA
treatment stimulated TSP1 gene expression in podocytes at the tran-
scriptional level.
The full-length human TSP1 promoter contains binding sites for
many transcription factors such as MAPK targets of c-jun, c-fos, CREB,
and c-myc. Moreover, ERK/JNK signaling pathways have been shown
to involve in leptin-induced TSP1 gene expression [34]. To determine
which signaling pathway is involved in FFA-induced TSP1 expression
in podocytes, pathway inhibitors were utilized. Human podocytes
were pre-incubated with MAPKs inhibitors including PD98059 (ERK
p42/44 inhibitor, at 10−5 mol/l), SB202190 (p38 inhibitor, at
10−5 mol/l) and SP600125 (JNK inhibitor, at 10−5 mol/l) for 2 h and
then treated with 125 μM of FFA for 24 h. As shown in Fig. 4, increased
TSP1 expression by FFA treatment was blocked by PD98059 (Fig. 4A),
SB202190 (Fig. 4B) and SP600125 (Fig. 4C), suggesting ERK and p38
MAPK dependent pathways.Ctr
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1330 W. Cui et al. / Biochimica et Biophysica Acta 1852 (2015) 1323–1333To further determine themechanisms of FFAmediatedMAPK activa-
tion and to determine whether FFA stimulates TSP1 gene expression
after uptake into cells through CD36-the fatty acid translocase, we iso-
lated podocytes from CD36 null mice and wild type mice. The effect of
FFA on TSP1 expression in these cells was determined. As shown in
Fig. 5, TSP1 mRNA or protein levels were not signiﬁcantly altered in
these cells after FFA treatment. This data suggest that FFA stimulated
TSP1 gene expression after uptake into podocyte through CD36. Based
on these observations, we suggest that FFA is uptaken into podocyte
through CD36 and activates MAPK pathway, leading to increased TSP1
gene transcription.
3.3. Recombinant TSP1 treatment induced human podocyte apoptosis and
increased podocyte permeability through a TGF-β independent mechanism
We determined whether TSP1 treatment could induce human
podocytes apoptosis and functional changes as shown in FFA treatment.
Recombinant human TSP 1 was added to the differentiated human
podocytes for 24 h. Annexin V/PI staining and podocyte BSA ﬁlter
assay were performed. As shown in Fig. 6A, percent of apoptotic cells
(Annexin V positive staining and PI negative staining) was increased
after TSP1 treatment, indicating that TSP1 treatment induced human
podocyte apoptosis. In addition, TSP1 treatment signiﬁcantly increased
albumin passage through podocytes, suggesting increased podocyte
permeability (Fig. 6B). Themechanisms of TSP1 induced podocyte inju-
ry were further determined. TSP1 is an important regulator for latent
TGF-β activation [35] and TGF-β induces podocyte apoptosis [36,37].
Therefore, we determined whether TSP1-induced podocyte apoptosis
is through activation of TGF-β dependent pathway. Functional blocking
anti-TGF-β antibody (15 μg/ml, R&D system) was used to pretreat
human podocyte. The effect of TSP1 on podocyte apoptosis and function
was examined. As shown in Figs. 6C–D, anti-TGF-β antibody had noTunel
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as mean ± SE (n = 10 mice/group). *, P b 0.05 vs. WT/lean group; #, P b 0.05 vs. WT/obese greffect on TSP1-induced podocyte apoptosis or functional changes, sug-
gesting that TSP1 induces podocyte apoptosis or dysfunction through
a TGF-β independent pathway.3.4. TSP1 mediated saturated FFA induced podocyte apoptosis through
interaction with CD36
CD36 is an integral membrane protein existing on the surface of
many cell types including podocytes. CD36 binds to many ligands in-
cluding TSP1, FFA, and collagen et al. [15,38,39]. It has been shown
that CD36 mediates apoptosis signaling induced by TSP1 in endothelial
cells [13], by ox-LDL inmacrophages [40], and by advanced end product
(AGE) or palmitate in tubular cell [38]. CD36 interacts with type 1 re-
peats domain of TSP1. The residues on CD36 molecule that speciﬁcally
interact with TSP1 have been identiﬁed-called CD36 peptide (p93–
110) [18,19]. This CD 36 peptide has been shown to inhibit the effect
of TSP1/CD36 interaction on TSP1 mediated macrophages activation
in vitro [41,42]. To determine whether TSP1 interaction with CD36me-
diated FFA-induced podocyte apoptosis, podocytes were treated with
FFA in the presence of CD36 peptide or scrambled control peptide for
24 h. After treatment, caspase 3 activity and podocyte BSA ﬁlter assay
were performed. In order to conﬁrm the TSP1 mediated effect in the
assay, TSP1 deﬁcient podocytes were also included. As shown in Figs.
7A–B, caspase 3 activity and BSA leakage from podocytes were in-
creased by FFA treatment. This FFA mediated effect was abolished in
TSP1 deﬁcient podocytes or in wild type podocytes after exposed to
CD36 peptide. In addition, CD36 peptide treatment had no effect on
FFA-mediated increase in TSP1 expression in podocytes (data not
shown). Taken together, these data suggest that interaction between
TSP1 and CD36 plays a role in FFA-induced podocyte apoptosis and
dysfunction.WT TSP1 KO
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in TSP1−/−mice or CD36−/− mice
The in vivo importance of TSP1 and CD36 in obesity-associated
podocyte injury was determined in the current study. We utilized the
diet-induced obesity mouse model in TSP1 deﬁcient mice as well as in
CD36 deﬁcient mice [11,12,22]. After 16 weeks of high fat diet feeding,
male TSP1−/− or CD36−/− mice were sacriﬁced. Kidney tissues
were collected for further analysis. Previously, we demonstrated that
glomeruli TSP1 (including in mesangial cells and podocytes) was in-
creased in high fat fed obesewild typemice [12]. In this study, glomer-
uli CD36 mRNA levels were comparable in four groups of mice
(Fig. 8A). However, podocyte functional markers, such as WT1,
nephrin and synaptopodin were decreased in obese wide type
mice. However, all these changes were attenuated in obese
TSP1−/−mice (Figs. 8B–D). Consistently, WT1 positive cells in glo-
merulus were signiﬁcantly reduced in obese WT mice but not in
obese TSP1−/− mice (Fig. 8E). Apoptotic cell number, positive
staining for active caspase 3 in kidney sections and caspase 3 activity
assay in isolated glomeruli were increased in obese wide type mice,
which were attenuated in either obese TSP1−/− mice (Fig. 9) or
CD36−/− mice (Fig. 10). Taken together, these data provide
in vivo evidence of the involvement of TSP1 and CD36 interaction
in mediating obesity-associated podocytopathy.
4. Discussion
In the current study, for the ﬁrst time, we demonstrated that saturat-
ed FFA stimulated TSP1 gene expression in human podocytes at the tran-
scriptional level. Moreover, increased TSP1 mediated FFA-inducedTunel
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staining (A). The scale bar represents 50 μm. In addition, glomerular caspase 3 protein expressio
caspase-3 colorimetric assay kit, respectively. Data are presented as mean ± SE (n = 6 mice/ghuman podocyte apoptosis and dysfunction partially through interaction
with its receptor CD36. Importantly, using a diet-induced obese mouse
model, our in vivo data demonstrated that obesity-associated podocyte
apoptosis and dysfunction were attenuated in TSP1−/−mice as well
as in CD36−/− mice. Taken together, these studies provide novel
vidence that the interaction of TSP1 with its receptor CD36 contributes
to obesity — associated podocytopathy.
Accumulating evidence has shown the strong correlation between
obesity and the development of albuminuria/proteinuria [43]. Previous-
ly, clinical studies demonstrated that glomeruli enlargement and
podocyte hypertrophy were found in extremely obese individuals
(BMI N 40 kg/m2) but not in age-matched nephrectomy patients with-
out obesity. Additionally, this renal pathology change was accompanied
by a signiﬁcantly increased twenty four-hour protein excretion in ex-
tremely obese individuals [44], suggesting that podocyte dysfunction
plays a key role in proteinuria formation in obese patients. Although
there are some advances in studying the obesity-associated podocyte
injury in recent years, the mechanisms are still not clear [45–48]. It is
known that obesity is associated with increased plasma levels of FFA
and increased FFA is an important cause of obesity-associated insulin re-
sistance and metabolic syndrome [49]. Recently, studies have shown
that podocytes are highly susceptible to the saturated FFA-induced
lipotoxicity. FFA induces ER stress and causes podocyte death [27,29,
50]. In the current study, consistently, podocyte apoptosis and dysfunc-
tion were induced either by FFA (palmitate) treatment in a dose depen-
dent manner in vitro or in a high fat diet induced obese mouse model
in vivo. These obese mice also developed albuminuria [12]. Using FFA-
induced podocyte apoptosis as a model, we further determined the
down-stream molecules that involved in FFA-induced podocyte injury
in the current study.WT CD36 KO
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protein, was up-regulated by FFA in podocyte. Recently, TSP1 has been
identiﬁed to be an adipokine, which is associated with obesity associat-
ed inﬂammation and insulin resistance [50]. TSP1 is also an important
mediator for various kidney diseases including obesity and diabetes re-
lated kidney complications [8,12,26,51]. Upon stimulation by various
factors, kidney cells produce and secrete TSP1, which then activates
the latent TGF-β and induces kidneyﬁbrosis [52–54]. Our previous stud-
ies demonstrated that obesity-associated albuminuria was attenuated
in obese TSP1 deﬁcientmice [12].Moreover, in TSP1 deﬁcientmesangial
cells, leptin's stimulatory effect on TGF-β-dependent matrix protein
production was abolished, suggesting a role of TSP1 in mesangial cell-
mediated ﬁbrosis and the development of albuminuria in the obese
state. In addition to mesangial cells, podocytes are another major
cellular sources of increased TSP1 expression in glomeruli under obese
conditions [12]. Therefore, in this study, the contribution of TSP1 to
obesity-associated podocyte injury was explored. In vitro data demon-
strated that FFA treatment stimulated TSP1 expression in human
podocyte at the transcription levels and involved in MAPK activation.
It is known that CD36 is a fatty acid translocase and regulates the uptake
of FFA into cells. The putative FFA binding site on CD36molecule (amino
acid residues 127–279) has been suggested by a study from Baillie et al.
[55]. Therefore, we determined whether FFA uptake is required for me-
diating TSP1 gene expression in podocytes. To do this, we isolated
podocytes from CD36 deﬁcient mice and treated these cells with FFA
to look at TSP1 expression.We found that FFA induced TSP1 expression
was abolished in CD36 deﬁcient podocytes, suggesting that FFA uptake
into cells via CD36 is required for stimulation of TSP1 gene expression in
podocytes. In addition, studies from vascular cells showed that TSP1
binding to CD36 can inhibit myristic acid uptake [56]. Therefore, a
potential negative feedback effect might exist on FFA induced TSP1 ex-
pression in podocytes. Through this mechanism, it is anticipated that
FFA treatment only increases TSP1 expression in podocytes to a certain
level.
Our data also showed that addition of puriﬁed TSP1 to culturemedia
induced podocyte apoptosis and increased albumin leakage from
cultured human podocytes. TSP1 is an important regulator for latent
TGF-β activation [35] and TGF-β induces podocyte apoptosis [36,37].
Therefore, we determined whether TSP1-induced podocyte apoptosis
or dysfunction is through activation of TGF-β dependent pathway. Our
results demonstrated that TSP1 induced podocyte apoptosis or dysfunc-
tionwas not affected by anti-TGF-β antibodypretreatment, suggesting a
TGF-β independent mechanism. Importantly, in vivo data showed that
TSP1 deﬁciency attenuated obesity induced podocyte apoptosis.
Together, these data provide evidence that TSP1 contributes to FFA/
obesity associated podocytopathy.
TSP1 is a large homotrimer, with an NH2-terminal domain,
procollagen homology domain, type I, type II and type III repeats, as
well as a COOH-terminal domain in each monomer [57]. By interacting
with a variety of different cell surface receptors, thediversity of domains
in TSP1 molecular determines the multiple biological activities of TSP1.
In addition to functioning as a fatty acid translocase andmediating fatty
acid uptake into cells [58,59], CD36 is a receptor for TSP1 and a mem-
brane glycoprotein existing on many cell types including podocytes
[15,38,39]. It has been shown that CD36 mediates apoptosis signaling
induced by TSP1 in endothelial cells [13], by ox-LDL in macrophages
[40], and by advanced end product (AGE) or palmitate in tubular cell
[38]. CD36 interacts with type 1 repeats domain of TSP1. The residues
on CD36 molecule that speciﬁcally interact with TSP1 have been
identiﬁed-called CD36 peptide (p93–110) [18,19], which is different
from the FFA binding sites (p127–279) [55]. This CD 36 peptide has
been shown to inhibit the effect of TSP1/CD36 interaction on TSP1 me-
diated macrophages activation in vitro [41,42]. To determine whether
TSP1/CD36 interaction mediates FFA-induced podocyte apoptosis,
podocytes were treated with FFA in the presence of CD36 peptide or
scrambled control peptide. We found that CD36 peptide treatment toblock TSP1 binding to CD36 signiﬁcantly reduced FFA-induced podocyte
apoptosis. The in vivo importance of TSP1/CD36 interaction on obesity-
associated podocyte injurywas supported by using high fat diet induced
obese CD36 deﬁcientmousemodel. CD36 deﬁciency attenuated obesity
associated podocyte apoptosis. Based on our observation, we propose
that under obese conditions, increased FFA enters into podocytes via
binding to CD36, leading to activation of MAKP pathway and stimula-
tion of TSP1 expression. The secreted TSP1 then binds to the different
sites on CD36 and induces podocyte apoptosis and dysfunction.
5. Conclusion
Our data suggest that TSP1/CD36 interaction mediates FFA/obesity
associated podocyte apoptosis and dysfunction, which may provide a
new therapeutic strategy for treatment of obesity induced renal
complications.
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